News – Page 40 – Alligator Bioscience

2019-05-15

Regulatory

Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO

Lund, Sweden, May 15, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will prese ...

2019-05-09

Lund, Sweden, May 9, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutical ...

2019-04-17

Lund, Sweden, April 17, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee in Alligator Bi ...

2019-04-17

Regulatory

First patient dosed in Phase I clinical study of ATOR-1015 Significant events January-March• First patient dosed in Phase I clinical study o ...

2019-04-11

Lund, Sweden, April 11, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that preclinical data on the CTLA-4 x OX40 bi ...

2019-04-10

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2019-04-10

Regulatory

Tumor-localizing properties of bispecific antibody demonstrated by live imaging Lund, Sweden, April 10, 2019 – Alligator Bioscience (Nasdaq ...

2019-04-02

Regulatory

Lund, Sweden, April 2, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ...

2019-03-22

Regulatory

Lund, Sweden, 22 March 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...